| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-06-08 | Merck Ventures (Germany) | € 150 million | investment - financing round | Merck KGaA (Germany) | Financing round | |
| 2016-06-08 | Lion Biotechnologies (USA - CA) | $100 million | private placement | institutional and other accredited investors | Cancer - Oncology | Private placement |
| 2016-06-08 | Pieris (Germany) | $16.5 million | private placement | Cancer - Oncology | Private placement | |
| 2016-06-06 | Vedanta Biosciences (USA - MA) | $50 million | financing round | Health For Life Capital (Seventure) (France) Invesco Asset Management (UK) PureTech (USA - MA) Rock Springs Capital (USA - MD) | Autoimmune diseases - Infectious diseases | Financing round |
| 2016-06-02 | LSP (Life Sciences Partners) (The Netherlands) | $280 million (€250,2 million) | financing round | Financing round | ||
| 2016-06-02 | Miragen Therapeutics (USA - CO) | up to $424,725 | grant | ALS association (USA -DC) | Neurodegenerative diseases | Grant |
| 2016-06-01 | Ablynx (Belgium) | € 74.2 million | private placement | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Private placement | |
| 2016-05-26 | Prometic Life Sciences (Canada) | $ 60 million | private placement | Private placement | ||
| 2016-05-24 | CEL-SCI Corporation (USA -VA) | $ 5 million | private placement | undisclosed single healthcare dedicated institutional investor | Cancer - Oncology | Private placement |
| 2016-05-17 | Nouscom (Switzerland) | € 12 million | series A financing round | LSP (The Netherlands) Versant Ventures (USA - CA) | Cancer - Oncology | Series A financing round |
| 2016-05-09 | AC Immune (Switzerland) | CHF 42.7 million (€ 38.64 million) | series E financing round | undisclosed institutions and existing shareholders | Neurological diseases - CNS diseases | Financing round |
| 2016-05-05 | Financing round | |||||
| 2016-05-05 | Genvec (USA - MD) | $5 million (€ 4.38 million) | private placement | Private placement | ||
| 2016-05-05 | Redhill Biopharma (Israel) Medical University of South Carolina (MUSC) (USA - SC) | $1.8 million | grant | National Cancer Institute (NCI) (USA) | Cancer - Oncology | Establishment of a new subsidiary in the EU |
| 2016-05-04 | Poxel (France) | IPO | Metabolic diseases | IPO | ||
| 2016-05-03 | Orchard Therapeutics (UK) | series A financing round | £21 million (€ 26.52 million) | F-Prime Capital (USA - MA) UCL Business (UK) UCL Technology Fund (UK) | Rare diseases - Genetic diseases - Hematological diseases - Immunological diseases - Metabolic diseases | Series A financing round |
| 2016-05-03 | Ideaya Bioscience (USA - CA) | $46 million | series A financing round | 5AM Ventures (USA - CA) Canaan Partners (USA - CA) Celgene (USA - NJ) WuXi Healthcare Ventures (China) Novartis Institute of Biomedical Research -Alexandria Real Estate | Cancer - Oncology | Series A financing round |
| 2016-05-02 | Acadia Pharmaceuticals (USA - CA) | $300 million | Private placement | |||
| 2016-04-20 | Enterome Bioscience (France) | €14.5 million | series C financing round | Seventure (France) Lundbeckfond Venture (Denmark) Nestlé Health Science (Switzerland) | Digestive diseases - Gastrointestinal diseases - Inflammatory diseases | Series C financing round |
| 2016-04-20 | PeptiMimesis (France) | €1.2 million ($1.4 million) | financing round | Cap Innov’Est (France) | Autoimmune diseases - Cancer - Oncology | Financing round |
